ResMed Delivers Strong Q3 Results and Margin Expansion

The latest update is out from Resmed ( (RMD) ).

On April 30, 2026, Resmed reported third-quarter fiscal 2026 results for the period ended March 31, 2026, posting an 11% year-on-year revenue increase to $1.43 billion, or 8% in constant currency, alongside a 290-basis-point expansion in gross margin and GAAP diluted EPS of $2.74. The company highlighted strong operating leverage with income from operations up 17%, non-GAAP EPS up 21%, robust operating cash flow of $554 million, and $262 million returned to shareholders, underscoring its momentum in sleep and breathing health markets and its strategic push to expand global access to home-based digital care.

The most recent analyst rating on (RMD) stock is a Buy with a $290.00 price target. To see the full list of analyst forecasts on Resmed stock, see the RMD Stock Forecast page.

Spark’s Take on RMD Stock

According to Spark, TipRanks’ AI Analyst, RMD is a Outperform.

The score is driven primarily by strong financial performance (high margins, low leverage, and robust free cash flow) and a favorable earnings call emphasizing margin progress, clear FY26 operating targets, and substantial capital returns. Offsetting factors are a premium valuation (P/E ~26) with a low yield and only moderate technical momentum.

To see Spark’s full report on RMD stock, click here.

More about Resmed

Resmed Inc. is a global medical technology company focused on sleep health, breathing disorders, and home-based healthcare. It develops and sells market-leading products and digital health solutions for sleep apnea and respiratory care, with shares listed on both the New York Stock Exchange and the Australian Securities Exchange.

Average Trading Volume: 1,096,259

Technical Sentiment Signal: Sell

Current Market Cap: $30.87B

For an in-depth examination of RMD stock, go to TipRanks’ Overview page.